{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"34.200","floor":"32.200"},"ipodate":{"start":"2019-10-16 00:00:00","end":"2019-10-21 00:00:00"},"minimumcapital":"3454.46","subscribed":"751.99","marketcap":"70.82億","H_marketcap":"--","pe":"--","codesrate":"9.00","link":"https://staticpdf.iqdii.com/stockdata/notice/06855/2019/2019101600008_c.pdf","ipopricing":"34.200","resultdate":"2019-10-25 00:00:00","enddate":"2019-10-21 00:00:00","listeddate":"2019-10-28 00:00:00","issuenumber":"1218.09萬","issuenumberhK":"609.05萬","issuenumberother":"609.04萬","grayprice":"52.10","sponsors":"美林遠東有限公司,花旗環球金融亞洲有限公司","raisemoney":"31170.00萬","use":"1、所得款項凈額約42%（約130.9百萬港元）分配到研發，將核心產品HQP1351商業化\n2、所得款項凈額約13%（約40.5百萬港元）用于APG-1252持續及規劃臨床試驗；\n3、所得款項凈額約19%（約59.2百萬港元）用于APG-2575持續及規劃臨床試驗；\n4、所得款項凈額約19%（約59.2百萬港元）用于APG-115持續及規劃臨床試驗；\n5、所得款項凈額約6%（約18.7百萬港元）分配到APG-1387及APG-2449其余臨床計劃的持續及規劃臨床試驗；\n6、所得款項凈額約1%（約3.1百萬港元）分配到我們的營運資金及一般公司用途。","shares":100,"leadagent":"美林(亞太)有限公司,花旗環球金融亞洲有限公司,華泰金融控股(香港)有限公司,建銀國際金融有限公司,華興證券(香港)有限公司,招銀國際金融有限公司,海通國際證券集團有限公司","bookrunners":"美林(亞太)有限公司,花旗環球金融亞洲有限公司,華泰金融控股(香港)有限公司,建銀國際金融有限公司,華興證券(香港)有限公司,招銀國際金融有限公司,海通國際證券集團有限公司","coordinator":"美林(亞太)有限公司,花旗環球金融亞洲有限公司,華泰金融控股(香港)有限公司","firstDayOpen":"53.00","IsEiio":0,"Interestdays":4,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"美林(亞太)有限公司","code":"E06855","name":"亞盛醫藥－Ｂ","fullname":"亞盛醫藥集團"},"institutioninfo":{"principaloffice":"中國江蘇省蘇州市蘇州工業園區星湖街218號B7樓7層","registrars":"卓佳證券登記有限公司","registrarstel":"(852) 2980 1333 ","chairman":"楊大俊","secretary":"王章旗","telephone":"(86512) 8555 7777","substantialshareholders":"Ascentage Limited(25.65%),Yuanming實體(9.87%),先進制造產業投資有限公司(9.21%),HealthQuest Pharma Limited(6.8%)","principalactivities":"公司為一間放眼全球的臨床階段生物科技公司，從事開發治療癌癥、HBV及衰老相關疾病的新型療法。","website":"http://www.ascentagepharma.com"},"managerinfo":[{"managername":"楊大俊","post":"董事會主席、執行董事兼首席執行官","rankno":1},{"managername":"王少萌","post":"非執行董事兼科學顧問委員會主席","rankno":2},{"managername":"田源","post":"非執行董事","rankno":3}],"investorinfo":[{"institutionname":"中國生物制藥有限公司","shareholding":"4,586,400.0","percentage":37.65,"ReleaseDate":"2020-04-28 00:00:00","relatedparty":"謝承潤","subsidiary":["中國生物制藥有限公司"],"InverstorType":"公司"}],"TotalShareholdingPercentage":37.65},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":11}